Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and three have issued a strong buy recommendation on the company.

A number of research firms recently issued reports on ZLDPF. BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th.

Zealand Pharma A/S Price Performance

Zealand Pharma A/S stock opened at $44.70 on Tuesday. The firm has a market capitalization of $3.20 billion, a P/E ratio of 3.32 and a beta of 0.86. Zealand Pharma A/S has a 1 year low of $35.93 and a 1 year high of $83.12. The business has a 50-day moving average of $47.94 and a 200-day moving average of $57.76. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $2.81 million. On average, equities analysts anticipate that Zealand Pharma A/S will post 2.37 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.